Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

(CRL)
  Report
Delayed Nyse  -  04:00:02 2023-03-24 pm EDT
193.79 USD   +0.04%
03/15Transcript : Charles River Laboratories International, Inc. Presents at Barclays Global Healthcare Conference, Mar-15-2023 10:15 AM
CI
03/14Charles River Launches Apollo, an Industry-Leading, Secure, Cloud-Based Platform for Real-Time Toxicology Study Data
AQ
03/13Charles River Launches Apollo™, an Industry-Leading, Secure, Cloud-Based Platform for Real-Time Toxicology Study Data
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Charles River Laboratories International, Inc. and Flagship’s Pioneering Medicines Enter Agreement Leveraging Ai-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs

02/16/2023 | 09:00am EDT

Charles River Laboratories International, Inc. announced a multi-program agreement with Pioneering Medicines, a strategic initiative of Pioneering, that gives Pioneering Medicines access to Logica™. Logica is an Artificial Intelligence (AI) powered drug solution that translates biological insights into optimized preclinical assets by leveraging Valo Health's AI-powered Opal Computational Platform and Charles River's leading preclinical expertise. Through the agreement, Pioneering Medicines will deploy Logica across a portfolio of targets with the aim of creating optimized small molecules that lead to novel therapies for unmet medical needs.

In 2022, Charles River and Valo Health, Inc. (“Valo”) launched Logica, leveraging Valo's AI-powered Opal Computational Platform and Charles River's leading preclinical expertise, providing clients with transformed drug discovery with a single integrated offering seamlessly translating targets to candidate nomination. Logica utilizes predictive models, chemical design and synthesis capabilities, DNA-encoded libraries, in silico high throughput screening from Valo's Opal Computational Platform as well as Charles River's leading capabilities in all aspects of discovery optimization including high throughput screening, medicinal chemistry, ADME, biology, pharmacology, and ultimately safety testing and IND submission, joining together for the first time to create a computation-powered, unified target-to-candidate offering. Logica is offered as a fully managed, risk-sharing model, with most of the client cost tied to success.


ę S&P Capital IQ 2023
All news about CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
03/15Transcript : Charles River Laboratories International, Inc. Presents at Barcl..
CI
03/14Charles River Launches Apollo, an Industry-Leading, Secure, Cloud-Based Platform for Re..
AQ
03/13Charles River Launches Apollo™, an Industry-Leading, Secure, Cloud-Based Platform..
BU
03/13Charles River Laboratories to Present at Barclays Global Healthcare Conference
BU
03/13Charles River Laboratories International, Inc. Launches Apollo, an Industry-Leading, Se..
CI
03/09Charles River Launches Helper Plasmid to Streamline Adeno-Associated Viral Vector Manuf..
BU
03/08Duke Energy Starts Operations at Pisgah Ridge Solar Project in Texas
MT
03/01MyMD Pharmaceuticals Announces Upcoming Presentation of Preclinical Rheumatoid Arthriti..
AQ
02/27UBS Adjusts Charles River Laboratories International's Price Target to $255 From $260, ..
MT
02/24Insider Buy: Charles River Laboratories International
MT
More news
Analyst Recommendations on CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
More recommendations
Financials (USD)
Sales 2023 4 112 M - -
Net income 2023 401 M - -
Net Debt 2023 2 013 M - -
P/E ratio 2023 24,9x
Yield 2023 -
Capitalization 9 880 M 9 880 M -
EV / Sales 2023 2,89x
EV / Sales 2024 2,52x
Nbr of Employees 20 700
Free-Float 98,8%
Chart CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Duration : Period :
Charles River Laboratories International, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 193,79 $
Average target price 256,50 $
Spread / Average Target 32,4%
EPS Revisions
Managers and Directors
James C. Foster General Counsel
Flavia H. Pease Chief Financial Officer & Executive Vice President
Mark Mintz Chief Information Officer & Senior Vice President
Julie Frearson Chief Scientific Officer & Senior Vice President
Birgit Girshick Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.-11.10%9 876
MODERNA, INC.-16.81%57 628
LONZA GROUP AG18.91%43 764
SEAGEN INC.54.15%37 067
IQVIA HOLDINGS INC.-8.24%34 916
ALNYLAM PHARMACEUTICALS, INC.-19.84%23 646
MarketScreener: Created by Investors for Investors!
100% Free Registration
fermer